NMN and NAD+: The Longevity Supplements With a $60/Month Price Tag and Uncertain Evidence

NAD+ (nicotinamide adenine dinucleotide) is one of the most important molecules in cell biology. It's a cofactor in hundreds of metabolic reactions, essential for DNA repair, and a substrate for sirtuins — proteins associated with longevity in animal models.

NAD+ levels decline with age. The supplement industry concluded: supplement NAD+ precursors → raise NAD+ → slow aging. The logic sounds airtight. The clinical evidence is more complicated.

What NAD+ does and why it declines

NAD+ exists in two forms: NAD+ (oxidized) and NADH (reduced). The ratio matters for cellular energy metabolism — the electron transport chain and ATP production depend on cycling between these forms.

Beyond energy:

• Sirtuins (SIRT1–7): NAD+-dependent deacetylases that regulate gene expression, stress response, DNA repair, and mitochondrial biogenesis. Sirtuin activity is reduced when NAD+ is low.
• PARPs: NAD+-consuming DNA repair enzymes. Activated by DNA damage; compete with sirtuins for NAD+.
• CD38: NAD+-consuming enzyme that increases with age and inflammation — a primary reason NAD+ declines.

NAD+ decline with age is well-documented in animal and human tissue samples. Age-related decline of ~50% in some tissues by middle age.

The precursor hierarchy

You can't take NAD+ directly — it doesn't cross cell membranes well. Precursors are used instead:

Nicotinamide Riboside (NR):

• Directly converted to NMN, then NAD+
• Well-absorbed; multiple human trials showing NAD+ elevation
• Marketed under Tru Niagen (ChromaDex patent)
• 300mg/day raises whole blood NAD+ by 40–90% in human trials

Nicotinamide Mononucleotide (NMN):

• One step closer to NAD+ than NR
• Requires Slc12a8 transporter for cellular uptake (debate about whether this transporter is active in all tissues)
• Raises blood NAD+ similarly to NR in human studies
• More expensive, more marketed, similar results to NR in practice

Nicotinamide (NAM) and Niacin (NA):

• Cheaper, less marketed
• Also raise NAD+ via the salvage pathway
• Niacin at high doses causes flushing; NAM may inhibit sirtuins at high doses
• Much cheaper than NR/NMN; less studied in this context

Tryptophan → NAD+: De novo synthesis pathway. Dietary tryptophan contributes to NAD+ pool but is inefficient.

What human studies actually show

NAD+ elevation: well-established

Multiple RCTs confirm NR and NMN raise blood NAD+ levels in humans:

• Martens et al. (2018): 500mg/day NR for 6 weeks raised whole blood NAD+ by 60% in older adults
• Yoshino et al. (2021): 250mg/day NMN for 10 weeks raised muscle NAD+ in postmenopausal women

This part is not debated. Both compounds do what they claim at the molecular level.

Clinical outcomes: much less clear

Insulin sensitivity: Yoshino et al. (2021) found NMN improved muscle insulin sensitivity in overweight postmenopausal women. One study; needs replication.

Muscle function in elderly: Some positive signals in small studies. Igarashi et al. (2022): NMN improved walking speed and grip strength in older adults. Small sample (n=42).

Cardiovascular: Preliminary data suggesting improved arterial stiffness in NR users. Not replicated at scale.

Cognitive function: No well-powered human RCT showing cognitive benefit in humans.

Fatigue/energy: Frequent anecdotal claim; not reliably shown in blinded RCTs.

Lifespan extension: Zero human data. This is a category error — you cannot test lifespan extension in human RCTs in any reasonable timeframe.

The animal-to-human translation problem

The longevity excitement originated from David Sinclair's lab (Harvard) and others showing:

• NAD+ supplementation extended lifespan in yeast, worms, mice
• Sirtuin activation in rodents produced impressive metabolic effects
• NMN reversed vascular aging and improved muscle function in old mice

These results are real. The translation to humans is uncertain because:

1. Species differences in NAD+ metabolism — mouse NAD+ dynamics differ from human
2. Dosing — mouse doses that showed effects don't scale linearly to humans
3. Baseline NAD+ status — lab mice are sedentary and often metabolically compromised; the effect of raising NAD+ may be different in healthier humans
4. Sirtuin biology — sirtuin activation's role in human aging is less established than in model organisms

David Sinclair himself takes NMN daily based on his research. He also acknowledges the human evidence is limited. That's an important distinction: the hypothesis is compelling; the human evidence is preliminary.

The CD38 problem nobody talks about

CD38 is a major NAD+-consuming enzyme that increases dramatically with age and with senescent cell accumulation. It may be the primary reason NAD+ declines with age.

Simply supplementing NAD+ precursors doesn't address elevated CD38. The NAD+ you add gets consumed faster by CD38.

Apigenin (a flavonoid from parsley/chamomile) inhibits CD38 and may therefore complement NR/NMN supplementation by reducing the drain. Some researchers stack these — apigenin + NR/NMN — for this reason. Not well-studied in humans.

Cost vs. evidence ratio

NR (Tru Niagen): ~$40–60/month
NMN (quality brands): ~$50–80/month

For comparison, compounds with stronger human evidence for metabolic and longevity-adjacent outcomes:

• Creatine: $10/month
• Magnesium glycinate: $10/month
• Vitamin D3: $5/month
• Exercise (free)

The cost of NR/NMN is not proportional to current human evidence strength.

Who might have a legitimate case for supplementing

• Older adults (50+) with metabolic concerns: Most human benefit signals come from this population; baseline NAD+ is lower, so the delta matters more
• People with confirmed mitochondrial dysfunction: NAD+ is central to mitochondrial function
• Those who have optimized sleep, exercise, and diet first: If lifestyle NAD+ support is maxed, supplementation may add marginal benefit
• Researchers or early adopters: If you understand the evidence is preliminary and want to participate in the n=1 experiment

Not well-justified for: Healthy young adults expecting anti-aging benefits based on mouse studies.

Dosing

• NR: 300–500mg/day. Well-studied dose range.
• NMN: 250–500mg/day. Similar NAD+ elevation to NR at these doses.
• Timing: Morning (NAD+ is involved in circadian rhythm regulation; some evidence late-day dosing disrupts sleep)
• With apigenin: 50–100mg apigenin if also targeting CD38 inhibition

The framework applied

For any NAD+ precursor study:

1. Was NAD+ actually measured? Many studies measure blood NAD+, which may not reflect intracellular tissue levels.
2. What tissue? Blood vs. muscle vs. brain NAD+ may respond differently.
3. What clinical outcome? Raising NAD+ is not the same as improving the clinical outcome being marketed.
4. What population? Older adults with lower baseline respond more than young healthy adults.
5. Industry funding? ChromaDex (NR) and NMN supplement companies fund much of the research.

We automated this at Q-SCI. Any study — paste it, get a quality score.

Bottom line

• NR and NMN reliably raise NAD+ levels in humans — this is established
• Clinical outcome evidence (metabolic, physical, cognitive) is preliminary — small studies, mostly in older adults
• The jump from "raises NAD+" to "extends healthy lifespan" is not supported by human data
• Most compelling for: adults 50+ with metabolic concerns who have optimized lifestyle factors first
• Niacin/NAM achieve similar NAD+ elevation at a fraction of the cost — less marketed, similar mechanism
• $50–80/month is a high price for preliminary evidence; optimize sleep, exercise, and diet first
• Apigenin as CD38 inhibitor is an interesting complement — speculative but mechanistically interesting

NAD+ biology is genuinely important. The supplements work at the molecular level. Whether that translates to meaningful human healthspan extension is the open question the marketing has already answered.

---

More evidence-based analyses at q-sci.org/blog. Score studies free at q-sci.org.